問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chung Shan Medical University Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 402Taichung CityTaichung South

Recruiting Trial

197Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

518Cases

2014-06-01 - 2015-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-05-30 - 2013-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-09-01 - 2024-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2011-10-01 - 2014-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2025-04-01 - 2027-12-31

Phase III

Active
A multicenter, open-label, randomized phase 3 trial evaluating sequential treatment with THIO followed by cemiplimab (LIBTAYO®) versus investigator’s choice of single-agent chemotherapy as third-line therapy in participants with advanced or metastatic non–small cell lung cancer (NSCLC).

  • Condition/Disease

    Advanced non–small cell lung cancer (NSCLC)

  • Test Drug

    LIBTAYO THIO

Participate Sites
10Sites

Recruiting10Sites

2008-01-01 - 2010-10-31

Others

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-04-01 - 2011-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2018-04-12 - 2019-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2008-12-25 - 2009-11-04

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2013-12-01 - 2018-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

1 10 11 12 13 14 52
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB